Blood protein clues may catch malnutrition early in cancer patients
NCT ID NCT03240835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether three blood proteins (pre-albumin, retinol binding protein, and transferrin) can help detect early malnutrition in people with advanced nasopharyngeal cancer undergoing chemoradiotherapy. Researchers tracked 60 patients to see if these proteins change during treatment and relate to weight loss and side effects. The goal is to find a simple way to monitor nutrition and intervene sooner.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
60 people
The number who actually took part.
- Started
-
Sep 2017
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
III-IVb(Union for International Cancer Control,UICC 8th) NPC patients with histologic diagnosis of World Health Organization(WHO) II/III
- Ages
-
18 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III) * All genders,range from 18~60 years old * Karnofsky performance status(KPS) ≥ 80 * Clinical stage III\~IVb(UICC 8th) * Without significant digestive system disease,nutritional and metabolic diseases or endocrine disease * Without significant cardiac,respiratory,kidney or liver disease * Not received radiotherapy, chemotherapy and other anti-tumor treatment(including immunotherapy) * white blood cell(WBC) count ≥ 4×109/L, neutrophile granulocyte(NE) count ≥ 1.5×109/L, Hemoglobin(HGB) ≥ 10g/L, platelet(PLT) count ≥ 100×109/L * alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \< 1.5×upper limit of normal(ULN), bilirubin \< 1.5×ULN, alanine aminotransferase (CCR) ≥ 30ml/min * Inform consent form Exclusion Criteria: * Distance metastases * Second malignancy within 5 years * Drug or alcohol addition * Do not have full capacity for civil acts * Active systemic infections * Chronic consumptions * Mental disorder * Pregnancy or lactation * Concurrent immunotherapy or hormone therapy for other diseases * Severe complication, eg, uncontrolled hypertension
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malnutrition are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can zapping liver and lung tumors boost treatment for nasopharyngeal cancer?
- Can IV nutrition at an outpatient clinic help malnourished surgery patients?
- Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
- Searching for biomarkers to combat malnutrition
- Can an experimental drug shrink advanced solid tumors?
- One diet plan to fight two forms of malnutrition in kids?